GO
Loading...

Novartis AG

More

  • European stocks end lower after US earning misses Tuesday, 27 Jan 2015 | 11:41 AM ET

    European markets closed down on Tuesday, after a number of Wall Street's biggest firms missed earnings expectations.

  • Novartis flags faster sales, profit growth for 2015 Tuesday, 27 Jan 2015 | 2:48 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Novartis forecast sales and profits to grow at a faster pace this year driven by recent drug successes and its portfolio overhaul.

  • *Core EPS $1.21 vs $1.18 forecast in Reuters poll. ZURICH, Jan 27- Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition. Novartis unveiled a transformative series of deals last year which will see it focus on a smaller number of...

  • We're looking for bolt-on acquisitions: Novartis CEO  Tuesday, 27 Jan 2015 | 1:45 AM ET

    Joe Jimenez, CEO of Novartis, says the company is looking to carry out merger and acquisition deals in 2015 to compliment its existing businesses.

  • Novartis CEO on euro, Swiss franc effect  Tuesday, 27 Jan 2015 | 1:45 AM ET

    Joe Jimenez, CEO of Novartis, says currency moves won't affect the growth of the underlying business.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • DUBLIN/ FRANKFURT, Jan 22- Business leaders in Europe gave a mixed welcome to the European Central Bank's moves to bolster growth and inflation in the euro area on Thursday, with many- especially in Germany- concerned the programme could delay unpopular economic reforms. "This is a step in the right direction and we'll have to watch and see how it plays out," Swiss...

  • We are funding part of ACA: Novartis CEO  Thursday, 22 Jan 2015 | 8:14 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Joe Jimenez, Novartis CEO, discusses how the move in the Swiss franc impacted his company, innovative drugs in the pipeline, and pharmaceutical pricing issues.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET

    Here are the fund managers Morningstar considers the best of the best.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • FDA approves Novartis's psoriasis drug Wednesday, 21 Jan 2015 | 12:49 PM ET

    Jan 21- The U.S. Food and Drug Administration said it approved Novartis AG's drug to treat adults with moderate to severe plaque psoriasis.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • LONDON, Jan 16- GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with Reuters, Andrew Witty also said he and his team had spent "a few days" exploring whether the drugmaker...

  • *Consumer more tenable as standalone business after Novartis deal. Chief Executive Andrew Witty told Reuters the group's large consumer health business would be more viable as a standalone operation following the conclusion of a $20 billion asset swap with Novartis, especially if it bought additional assets. "Post- Novartis, particularly if we did more...

  • *Bank of America, Citi fall after results. *Swiss National Bank scraps three-year-old euro cap on franc. "We're probably going to see slowing in the global economy, and it will be very difficult to sail through a global recession without getting touched," said Scott Colyer, chief executive officer of Advisors Asset Management in Monument, Colorado.

  • *Bank of America, Citi down after results. *Swiss National Bank moves to scrap 3- year euro cap on the franc. Swiss stocks traded in the United States moved higher, Credit Suisse, up 0.7 percent at $22.98 and Novartis, up 1.9 percent to $98.61, as a strengthening Swiss franc made U.S.-dollar denominated stocks cheaper.

  • Midday movers: Credit Suisse, UBS, Citigroup & more Thursday, 15 Jan 2015 | 12:42 PM ET

    Some of Thursday's midday movers:

  • A 'tattoo' may end fingerpricks for diabetics Thursday, 15 Jan 2015 | 11:56 AM ET
    Joseph Wanf

    Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.

  • US STOCKS-Wall St flat in volatile trade after Swiss move Thursday, 15 Jan 2015 | 11:03 AM ET

    *Bank of America, Citi down after results. NEW YORK, Jan 15- U.S. stocks were little changed in choppy trading on Thursday, as investors wrestled with the ramifications with a move by the Swiss National Bank to scrap its three-year euro cap on the franc. Swiss stocks traded in the U.S. moved higher, Credit Suisse, up 0.7 percent at $22.98 and Novartis, up 1.9 percent to...

  • US STOCKS-Wall St drops after Swiss move; banks tumble Thursday, 15 Jan 2015 | 9:56 AM ET

    *Bank of America, Citi down after results. NEW YORK, Jan 15- U.S. stocks fell, erasing small gains at the open on Thursday, as investors grappled with a move by the Swiss National Bank to scrap its three-year euro cap on the franc. Swiss stocks traded in the U.S. moved higher, including UBS, up 2.4 percent at $16.87, Credit Suisse, up 3.2 percent at $23.55 and Novartis, up 1.9...